Tadalafil Tablet, Film Coated
Product Images NDC 72789-408

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 72789-408). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

72789408 Label (72789408)

Label for Tadalafil USP 10 mg tablets by PD-Rx Pharmaceuticals, Inc. The label shows a prescription drug with a package of 30 film-coated tablets for oral use. Includes dosage and storage warnings, reorder number, lot number H24B20, and expiration date 11/2025. The NDC is 72789-408-30.*

FDA Label Image

Tadalafil-figure-1 (Tadalafil Figure 1)

A set of four line graphs showing the difference in blood pressure (Tadalafil minus placebo) over time in hours. The graphs display standing systolic BP, standing diastolic BP, supine systolic BP, and supine diastolic BP, each with error bars indicating variability. The y-axis represents the difference in mmHg, and the x-axis represents time up to 96 hours.*

FDA Label Image

Tadalafil-figure-2 (Tadalafil Figure 2)

This figure shows two line graphs depicting standing and supine systolic blood pressure (BP) changes over a 24-hour period post-dose. The graphs compare the effects of Tadalafil 20 mg with doxazosin 8 mg versus placebo with doxazosin 8 mg on systolic BP, with time post-dose on the x-axis and systolic BP change (mmHg) on the y-axis.*

FDA Label Image

Tadalafil-figure-3 (Tadalafil Figure 3)

Line graph depicting changes in systolic blood pressure (mmHg) over 12 hours following administration of either 20 mg tadalafil or placebo, each combined with 8 mg doxazosin. Four conditions are shown based on dosing time (08:00 or 20:00) and treatment type, illustrating blood pressure trends post-dosing.*

FDA Label Image

Tadalafil-figure-4 (Tadalafil Figure 4)

A line graph showing plasma tadalafil concentration (µg/L) over time (hours) for three dosing regimens: single 20-mg dose, single 5-mg dose, and once-daily 5-mg dose following 5 consecutive days of administration. The graph includes error bars representing variability at each time point.*

FDA Label Image

Tadalafil-figure-5 (Tadalafil Figure 5)

A line graph comparing the change from baseline in IPSS total score over 12 weeks between Tadalafil 5 mg tablets and placebo. The x-axis shows treatment duration in weeks, and the y-axis shows change from baseline. The Tadalafil group shows a greater decrease in IPSS score compared to placebo, with statistical significance (P < 0.01).*

FDA Label Image

Tadalafil-figure-6 (Tadalafil Figure 6)

A line graph comparing change from baseline in IPSS total score over 12 weeks of treatment for Tadalafil Tablets 5 mg versus placebo. The x-axis shows treatment duration in weeks, and the y-axis shows change from baseline score. Tadalafil shows a greater reduction in score over time compared to placebo, with an asterisk indicating statistical significance at P < 0.01.*

FDA Label Image

Tadalafil-figure-7 (Tadalafil Figure 7)

A line graph showing least-squares mean change from baseline over 26 weeks of therapy comparing Tadalafil/Finasteride and Placebo/Finasteride. The x-axis represents weeks of therapy (0, 4, 12, 26), and the y-axis shows the LS mean change from baseline, ranging from 0.0 to -7.0. The graph includes annotations for statistical significance at certain points.*

FDA Label Image

Tadalafil-figure-8 (Tadalafil Figure 8)

A line graph comparing the change from baseline in IPSS Total Score over 12 weeks between Tadalafil 5 mg tablets and placebo. The graph shows a greater decrease in IPSS score for Tadalafil over time, with statistically significant differences noted at 12 weeks. X-axis represents treatment duration in weeks, Y-axis shows score change.*

FDA Label Image

Tadalafil-structure (Tadalafil Structure)

Chemical structure diagram of tadalafil showing the molecular arrangement of atoms including fused ring systems and functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.